Clinical trial
Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone…
NCT00450970 · Agennix, Industry · Terminated
Key facts
| NCT number | NCT00450970 |
|---|---|
| Title | Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) |
| Official title | Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA) |
| Acronym | SPERA |
| Lead sponsor | Agennix, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Oral Satraplatin |
| Enrollment | 344 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Mar 22, 2007 |
| Last update posted | Aug 17, 2012 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: